



MEMO

TO: Subcommittee on Procedures Review
FROM: John Stiver, SC&A
DATE: August 25, 2014
SUBJECT: Current Status of Program Evaluation Report (PER) Reviews

This memo provides the Subcommittee with an update on the status of PER reviews:

Table 1, “PER Review Status as of August 2014,” has been updated to reflect the status of recently completed PER Reviews. Specifically, refer to pages 4–6 of this memo. Updated information is presented in bolded blue text for easy identification.

Table 2, “New PERs Not Assigned for SC&A’s Review as of August 2014,” provides a list and descriptions of PERs recommended, but not yet been assigned, for review.

Table 3, “PER (Subtask 4) Case Reviews for Assigned PER Reviews Not Completed as of August 2014,” provides a listing of Subtask 4 case reviews that have not yet been completed.

Table 1. PER Review Status as of August 2014

PER	Title	Description	Notes
OCAS-PER-010 Rev-0 (April 13, 2007)	The Effect of Rocky Flats Neutron Dose Reconstruction Project Data	The Rocky Flats Neutron Dose Reconstruction Project (NDRP) was initiated to re-evaluate some original neutron dosimetry results. Additional neutron doses resulting from the efforts of the NDRP made it necessary to reassess completed Rocky Flats DRs.	PRSC decided to defer this PER for review at the July 31, 2012, SC meeting because SEC issues were still open. (July 31, 2012, transcript, p 310)
OCAS-PER-0013 Rev-0 (August 13, 2007)	Evaluation of the Impact of Changes to the Isotopic Ratios in for the Paducah Gaseous Diffusion Plant	Changes to ORAUT-TKBS-0019-5 resulted in identifying 734 potentially affected claims.	PRSC decided to defer this PER for review at the July 31, 2012 SC meeting because TBD issues were still open (July 31, 2012, transcript, p. 280).
OCAS-PER-0015 Rev 0 (July 31, 2007)	Mallinckrodt TBD Revision	The Mallinckrodt TBD (ORAUT-TKBS-0005) was revised due to issues raised during an SEC review and the granting of an SEC status. Some changes to the methodology will increase dose and, due to the SEC, some exposure pathways will be eliminated. Therefore, it is not possible to determine the effect on POC without a new dose estimate.	PRSC decided not to review this PER at the November 1, 2012, SC meeting. Determined resources would be best spent elsewhere (November 1, 2012, transcript, p. 162)
OCAS-PER-0016 Rev-0 (September 25, 2007)	Implementation of IREP Procedure for Claims near 50% Probability of Causation	In June 2006, the procedure for further evaluation of claims with POC values between 45% and 50% was revised. This change required the reassessment of numerous claims with POCs near 50%.	PRSC decided to defer this PER for review at the July 31, 2012, SC meeting. Determined resources would be best spent elsewhere (July 31, 2012, transcript, p. 301)
OCAS-PER-019 Rev-0 (May 18, 2007)	The Effect of Additional Neutron Dose Data from the Savannah River Site	The Savannah River Site (SRS) notified NIOSH that not all neutron dosimetry data were sent for several claims. After receiving the additional data, it was necessary to re-evaluate completed claims: 17 claims initially identified; 4 required re-evaluation.	PRSC decided not to review this PER at the November 1, 2012, SC meeting. Determined resources would be best spent elsewhere (November 1, 2012, transcript, p. 161)
OCAS-PER-0022 Rev-0 (September 20, 2007)	Chapman Valve TBD Revision	Revised DR methodology for internal dose. Revision 1 provides a constant intake of uranium while revision 0 provided for a lognormal distribution of intakes. Ten claims re-evaluated.	PRSC decided to defer this PER for review at the November 1, 2012, SC meeting because TBD revisions may have required a new PER. DCAS was to verify. (November 1 2012 transcript, p. 168)
OCAS-PER-0023 Rev-0 (September 20, 2007)	Argonne National Lab-West TBD Revision	Change requires that an annual x-ray be assigned when no medical records were received. There were 22 potentially affected claims.	PRSC decided to defer this PER for review at the November 1, 2012 SC meeting because dose impact was low and few cases affected. (November 1 2012 transcript, p. 154)

Table 1. PER Review Status as of August 2014

PER	Title	Description	Notes
OCAS-PER-0024 Rev-0 (September 25, 2007)	General Steel Industries TBD Approval	New TBD will require review of 4 claims.	PRSC decided to defer this PER for review at the November 1, 2012 SC meeting because site profile and SEC issues were open. (November 1 2012 transcript, p. 174)
OCAS-PER-026 Rev-0 (October 31, 2007)	Pantex TBD Revision - ORAUT-TKBS-0013	Revised the assigned dose for x-ray examinations for some organs during specific time frames. Potentially affects 50 claims.	PRSC decided to defer this PER for review at the November 1, 2012 SC meeting because SEC likely reduced the number of effected claims and dose impact was minimal. (November 1 2012 transcript, p. 144)
OCAS-PER-027 Rev-0 (October 30, 2007)	Clarksville and Medina Site Profile – ORAU-TBKS-0039	New TBD will require review of 65 claims. Some Clarksville/Medina Site claims were completed using information developed for the TBD prior to its issuance. Due to TBD changes during the comment resolution process, the doses assigned to the pre-TBD claims were underestimated.	PRSC decided to defer this PER for review at the July 31, 2012 SC meeting because SEC likely reduced the number of effected claims and may have taken issues off the table. DCAS was to verify. (July 31 2012 transcript, p. 314)
OCAS-PER-028 Rev-0 (October 30, 2007)	Pinellas TBD Revision	It is possible that missed photon dose was not included for 24 monitored workers when it should have been for dose reconstructions that were completed between 8/3/2006 and 11/8/2006.	PRSC decided to defer this PER for review at the November 1, 2012 SC meeting because PER predates TBD revisions, for which issues remain open (November 1 2012 transcript, p. 152).
OCAS-PER-0032 Rev-0 (December 18, 2007)	Nevada Test Site TBD Revisions	External dose changes included an increase in detection limits of the dosimeter used after 1986 and an adjustment to missed and recorded photon dose from July 1960 to the end of 1965. Potentially affects 481 claims.	PRSC decided to defer this PER for review at the July 31, 2012 SC meeting because SEC likely reduced the number of effected claims and dose impact is small. (July 31 2012 transcript, p. 293)
DCAS-PER-034 Rev-0 (December 9, 2011)	Harshaw Chemical Company TBD Revision	Increase in the dose estimate due to an increase in the estimated intake rate for type S uranium from 12/1/1949 to 12/31/1953.	PRSC decided to defer this PER for review at the November 1, 2012 SC meeting pending DCAS review of reason for changed U intake rate. (November 1 2012 transcript,p. 170)
DCAS-PER-036 Rev-0 (April 5, 2012)	Blockson TBD Revision	Considers the changes that were made between revision 2 and revision 3 of DCAS-TKBS-0002.	PRSC decided to defer this PER for review at the November 1, 2012 SC meeting because dose impact is small and few cases affected. (November 1 2012 transcript, p. 147)

Table 1. PER Review Status as of August 2014

PER	Title	Description	Notes
DCAS-PER-039 Rev-0 (January 7, 2013)	Baker Perkins TBD Revision	Several changes in the methods used to reconstruct doses at Baker-Perkins resulted in both inhalation and external doses being higher for some job categories when compared to previous methods. <u>Note:</u> only 8 claims complete, all 8 had POCs <50%.	Recommend pre-review. PRSC does <u>not</u> recommend review.
DCAS-PER-041 Rev-0 (July 12, 2012)	Revision to ORAUT-OTIB-0006, Dose Reconstruction from Occupational Medical X-ray Procedures	Adds organ dose data from lordotic and oblique chest X-rays, chest fluoroscopy, thoracic and cervical spine X-rays, and skin doses for all procedures. Several changes to the estimated dose were made in revision 4. The changes that resulted in increases in the estimated doses are: <ul style="list-style-type: none"> • An increase in the estimated dose from a lateral projection of a lumbar spine x-ray for all years for the stomach, bone surfaces, liver, gall bladder, spleen and remainder organs. • Increase in the estimated dose to the ovaries from pelvic x-rays through the end of 1970. Affected sites: Harshaw Brookhaven Extrusion Plant Paducah GDP	Recommend pre-review Selected for pre-review at March 19, 2014, Board teleconference. SC&A submitted pre-review report April 10, 2014 (SCA-TR-PR2014-0003). SC&A's pre-evaluation did <u>not</u> recommend performing a review of this PER. At the April 16, 2014, PRSC meeting, SC agreed with SC&A's recommendation to <u>not</u> review PER-041.

Table 1. PER Review Status as of August 2014

PER	Title	Description	Notes
DCAS-PER-042 Rev-0 (November 16, 2012)	Linde Ceramics Plant Technical Basis Document Revision	<p>Revision to incorporate changes associated with SEC-0154. Incorporates formal internal and NIOSH review comments. Constitutes a total rewrite of the document. The selection criteria resulted in 78 claims requiring further evaluation.</p> <p>Revision 3 of the TBD included the assignment of dose in the utility tunnels that was higher than any of the previous versions of the TBD. Other changes affected the distribution used for the reconstruction of internal doses. One such example is the intakes assessed for trades workers from 1955 to 1969. The estimate of those intakes went from using a distribution to assigning a constant that was higher than the geometric mean of the distribution but lower than the 95th percentile of the distribution</p>	<p>Recommend pre-review</p> <p>Selected for pre-review at March 19, 2014, Board teleconference. SC&A submitted pre-review report April 10, 2014 (SCA-TR-PR2014-0003). SC&A's pre-evaluation recommended performing a review of this PER.</p> <p>At the April 16, 2014, PRSC meeting, SC agreed with SC&A's recommendation to review the PER.</p> <p>SC&A submitted review of PER-042 on August 19, 2014.</p>
DCAS-PER-043 Rev-0 (June 7, 2013)	Internal Dosimetry Organ, External Dosimetry Organ, and IREP Model Selection by ICD-9 Code Revision (June 7, 2013)	<p>As part of this PER, thirty six claims were re-evaluated to determine the effect of revisions to OTIB-5. Two claims resulted in a new probability of causation greater than 50%, both as a result of changing the internal dose target organ from gallbladder to liver for code 155.1. None of the remaining thirty four claims exceeded a probability of causation of 45%. NIOSH will provide the Department of Labor with the list of the thirty-six claims evaluated under this PER. NIOSH will also request from the Department of Labor that the two claims now greater than 50% be returned to NIOSH for a new dose reconstruction.</p>	<p>Recommend pre-review</p> <p>Selected for pre-review at March 19, 2014, Board teleconference. SC&A submitted pre-review report April 10, 2014 (SCA-TR-PR2014-0003). SC&A's pre-evaluation recommended performing a review of this PER.</p> <p>At the April 16, 2014 PRSC meeting, SC agreed with SC&A's recommendation to review the PER.</p> <p>SC&A submitted review of PER-043 on August 18, 2014.</p>

Table 1. PER Review Status as of August 2014

PER	Title	Description	Notes
DCAS-PER-044 Rev-0 (May 16, 2013)	Metallurgical Laboratory	No TBD exists for Metallurgical Laboratory claims. However, the following changes have occurred (1) dates of the operational and residual periods changed; (2) an SEC was designated; and (3) some previous dose reconstructions referenced ORAUT-OTIB-0070 which was revised on 3/5/2012. <u>Note:</u> Only 1 claim affected.	<p>Selected for pre-review at March 19, 2014 Board teleconference. SC&A submitted pre-review report April 10, 2014 (SCA-TR-PR2014-0003). SC&A's pre-evaluation did <u>not</u> recommend performing a review of this PER.</p> <p>At the April 16, 2014 PRSC meeting, SC agreed with SC&A's recommendation to <u>not</u> review PER-044.</p>
DCAS-PER-045 Rev-0 (May 13, 2013)	Aliquippa Forge TBD Revision	Revision initiated due to comments from the DRSC. Residual period approach updated per ORAUT-OTIB-0070 and additional data capture information. Added an internal approach to account for D&D operations in 1988 and 1993/1994. There were 26 claims affected.	<p>Recommend pre-review</p> <p>Selected for pre-review at March 19, 2014 Board teleconference. SC&A submitted pre-review report April 10, 2014 (SCA-TR-PR2014-0003). SC&A's pre-evaluation recommended performing a review of this PER.</p> <p>At the April 16, 2014 PRSC meeting, SC agreed with SC&A's recommendation to review the PER.</p> <p>SC&A submitted review of PER-045 on August 20, 2014.</p>
DCAS-PER-048 Rev-0 (September 27, 2013)	Wah Chang	No TBD exists for Wah Chang claims. However, the following changes have occurred (1) dates of the operational and residual periods changed; (2) an SEC was designated; and (3) some previous dose reconstructions referenced ORAUT-OTIB-0070 which was revised on 3/5/2012. <u>Note:</u> Only 1 claim affected. There were 113 claims re-evaluated.	<p>Recommend pre-review</p> <p>PRSC does <u>not</u> recommend review.</p>

Table 2. New PERs Not Assigned for SC&A's Review as of August 2014

PER	Title	Description	Notes
DCAS-PER-047 Rev-0 (March 26, 2014)	NIOSH/DCAS Program Evaluation Report: Grand Junction Operations Office	No TBD exists for Grand Junction Operations Office (GJOO) cases. However, a template has been used as guidance to complete claims. As a result of the evaluation of a SEC petition, the template was edited on 9/5/2012 to incorporate the additional information. This PER is intended to evaluate the effect of these changes on previous dose reconstructions. The selection criteria resulted in re-evaluation of 24 claims.	Recommend pre-review at August 28, 2014, PRSC meeting
DCAS-PER-050 Rev-0 (March 13, 2014)	Program Evaluation Report: Bliss and Laughlin Appendix	Bliss and Laughlin dose estimates are currently completed using site specific methods formalized in Appendix D of Battelle-TBD-6000, which was issued on 9/11/2012. Prior to the issuance of Appendix D, claims were completed using Battelle-TBD-6000 without site specific guidance. Prior to that, ORAUT-OTIB-0004 was used to complete these claims. . This PER is intended to evaluate the effect of these changes on previous dose reconstructions. There were 27 claims re-evaluated under this PER.	Recommend pre-review at August 28, 2014, PRSC meeting
DCAS-PER-052 Rev-0 (March 25, 2014)	Program Evaluation Report: Westinghouse Nuclear Fuels Division	No TBD exists for the Westinghouse Nuclear Fuels Division site, but a template has been used as guidance to complete claims. Due to the discovery of additional air sample data, the unmonitored intakes used in template were updated on 6/8/2012. This PER evaluates the effect of this change on previous dose reconstructions. There were 68 claims re-evaluated under this PER.	Recommend pre-review at August 28, 2014, PRSC meeting
DCAS-PER-054 Rev-0 (July 25, 2014)	PER 54: Carborundum Company	No TBD exists for the Carborundum site. However, a template has been used as guidance to complete claims. Many of these claims utilized the ORAUT-OTIB-00070 depletion factor, which was revised on 3/5/2012 and this revision could affect previously completed Carborundum claims. In addition, the covered period for Carborundum was increased in 2009 to include 1943. There were 58 claims re-evaluated under this PER.	Recommend pre-review at August 28, 2014, PRSC meeting

Table 3. PER (Subtask 4) Case Reviews for Assigned PER Reviews Not Completed as of August 2014

PER	Title	Description
OCAS-PER-002	Error in surrogate organ assignment resulting in an underestimate of x-ray dose in SRS dose reconstructions	3 claims re-evaluated by NIOSH
OCAS-PER-003	Evaluation of the Effect of Adding Ingestion Intakes to Bethlehem Steel Cases	6 claims re-evaluated by NIOSH
OCAS-PER-004	Application of photofluorography at the Pinellas Plant	11 potentially affected claims
OCAS-PER-007	Evaluation of the Effect of Revision 2 of the Site Profile on Previously Completed Bethlehem Steel Cases	22 claims re-evaluated by NIOSH
OCAS-PER-008	Modification of NIOSH-IREP lung cancer risk model: effect of “combined” lung model on non-compensable lung cancer claims	8 claims re-evaluated by NIOSH
OCAS-PER-029	Hanford TBD Revisions*	1,190 potentially affected claims
DCAS-PER-038	Hooker Electrochemical TBD Revisions	20 claims re-evaluated by NIOSH (3 cases have been assigned for review, and the review of those cases is underway.)
* Transferred to Hanford Work Group.		